JP2018520679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520679A5 JP2018520679A5 JP2017568207A JP2017568207A JP2018520679A5 JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5 JP 2017568207 A JP2017568207 A JP 2017568207A JP 2017568207 A JP2017568207 A JP 2017568207A JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- recombinant cell
- intracellular signaling
- protein
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 108091008042 inhibitory receptors Proteins 0.000 claims description 18
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 claims description 17
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 claims description 17
- 108091005703 transmembrane proteins Proteins 0.000 claims description 13
- 102000035160 transmembrane proteins Human genes 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000005965 immune activity Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186108P | 2015-06-29 | 2015-06-29 | |
| US62/186,108 | 2015-06-29 | ||
| PCT/US2016/040010 WO2017004150A1 (en) | 2015-06-29 | 2016-06-29 | Immune checkpoint chimeric antigen receptors therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520679A JP2018520679A (ja) | 2018-08-02 |
| JP2018520679A5 true JP2018520679A5 (enExample) | 2019-08-08 |
Family
ID=57609024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568207A Pending JP2018520679A (ja) | 2015-06-29 | 2016-06-29 | 免疫チェックポイントキメラ抗原受容体療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180185434A1 (enExample) |
| EP (1) | EP3313892A4 (enExample) |
| JP (1) | JP2018520679A (enExample) |
| KR (1) | KR20180038447A (enExample) |
| CN (1) | CN108137707A (enExample) |
| AU (1) | AU2016285859A1 (enExample) |
| CA (1) | CA2991040A1 (enExample) |
| HK (2) | HK1254820A1 (enExample) |
| IL (1) | IL256643A (enExample) |
| MA (1) | MA42272A (enExample) |
| MX (1) | MX2018000278A (enExample) |
| WO (1) | WO2017004150A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| SG11201510740YA (en) | 2013-09-17 | 2016-01-28 | Obi Pharma Inc | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| FI3909972T3 (fi) | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
| JP2018518978A (ja) * | 2015-07-08 | 2018-07-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ） |
| US10590169B2 (en) * | 2015-12-09 | 2020-03-17 | Virogin Biotech Canada Ltd | Compositions and methods for inhibiting CD279 interactions |
| AU2017236069B2 (en) * | 2016-03-23 | 2021-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of PD-1 and 4-1BB |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| AU2017252128B2 (en) | 2016-04-22 | 2024-06-06 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens |
| KR20230117482A (ko) | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR20190096969A (ko) * | 2016-12-22 | 2019-08-20 | 윈드밀 테라퓨틱스, 인크. | 면역계를 조절하기 위한 조성물 및 방법 |
| AU2018245749A1 (en) | 2017-03-27 | 2019-10-03 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| KR20210098485A (ko) * | 2018-11-30 | 2021-08-10 | 윈드밀 테라퓨틱스, 인크. | 키메라 항원 수용체(car)를 발현하는 골수 침윤성 림프구(mil), 이를 제조하는 방법 및 치료에 사용하는 방법 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2022098985A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Glioblastoma specific marrow infiltrating lymphocytes and uses thereof |
| EP4248214A4 (en) * | 2020-11-19 | 2024-07-10 | OBI Pharma, Inc. | ACTIVE CANCER IMMUNOTHERAPY THROUGH IMMUNOMODULATION VIA GLOBO-SERIES ANTIGENS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842368A1 (en) * | 2011-07-29 | 2013-02-07 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| RU2725542C2 (ru) * | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| EP4205749A1 (en) * | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| WO2016037054A1 (en) * | 2014-09-04 | 2016-03-10 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| FI3909972T3 (fi) * | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
-
2016
- 2016-06-29 WO PCT/US2016/040010 patent/WO2017004150A1/en not_active Ceased
- 2016-06-29 AU AU2016285859A patent/AU2016285859A1/en not_active Abandoned
- 2016-06-29 HK HK18113910.0A patent/HK1254820A1/zh unknown
- 2016-06-29 JP JP2017568207A patent/JP2018520679A/ja active Pending
- 2016-06-29 KR KR1020187002679A patent/KR20180038447A/ko not_active Withdrawn
- 2016-06-29 MA MA042272A patent/MA42272A/fr unknown
- 2016-06-29 CN CN201680048831.3A patent/CN108137707A/zh active Pending
- 2016-06-29 CA CA2991040A patent/CA2991040A1/en not_active Abandoned
- 2016-06-29 HK HK18114773.4A patent/HK1255637A1/zh unknown
- 2016-06-29 EP EP16818647.6A patent/EP3313892A4/en not_active Withdrawn
- 2016-06-29 MX MX2018000278A patent/MX2018000278A/es unknown
- 2016-06-29 US US15/740,981 patent/US20180185434A1/en not_active Abandoned
-
2017
- 2017-12-28 IL IL256643A patent/IL256643A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520679A5 (enExample) | ||
| JP7026161B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| Mitra et al. | Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps | |
| van Montfoort et al. | NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines | |
| Gargett et al. | GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade | |
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| Sehgal et al. | Programmed death-1 checkpoint blockade in acute myeloid leukemia | |
| Barber et al. | Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma | |
| JP2020512284A5 (enExample) | ||
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2016520074A5 (enExample) | ||
| EP4545639A2 (en) | Engineered gamma delta t-cells | |
| JP2017513478A5 (enExample) | ||
| JP2017535292A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2018522592A5 (enExample) | ||
| RS63574B1 (sr) | Metode za povećanje efikasnosti imuno ćelija | |
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| Tang et al. | CD137 co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo | |
| JP2016534717A5 (enExample) | ||
| JP2019518460A5 (enExample) | ||
| Merker et al. | Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children | |
| Tal et al. | An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities |